OCRA News

OCRA Earns 4-Star Charity Navigator Rating for Ninth Consecutive Year

(February 5, 2019) OCRA is pleased to announce we have earned our NINTH consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator…

Read on

World Cancer Day is February 4th. Help Create a World Without Ovarian Cancer.

February 4th is World Cancer Day. Today, millions of people across the globe raise a collective voice for progress. Against cancer in its many insidious forms, and for access to treatments and care for those who need it, no matter where they live…

Read on

Drugs to Treat Hypertension May Enhance Ovarian Cancer Drugs

(January 23, 2019) Researchers at Massachusetts General Hospital recently found a correlation between a class of drug used to treat hypertension and longer survival rates in ovarian cancer patients when used with paclitaxel, a drug used to treat…

Read on

Chef Elle Simone to Host OCRA’s Turn Up the Heat DC

Another reason you don’t want to miss OCRA’s Turn Up the Heat! Not only does the event feature fabulous tastings from DC’s female culinary stars—we are thrilled to announce that the amazing Chef Elle Simone, from PBS’…

Read on

OCRA Awards $5.25 Million in Scientific Research Grants for 2019

(January 10, 2019) We’re pleased to announce OCRA’s newest research grants of $5.25 million to 23 top scientists at 14 top medical centers…

Read on

Turn Up the Heat at OCRA’s Foodie Fest

OCRA’s Turn Up the Heat is coming March 5th! Get your tickets now and treat yourself to our fabulous foodie fest, packed full of tantalizing treats and eats from the DC area’s most exciting female chefs, mixologists and restaurateurs…

Read on

OCRA Funded Research Delves Deeper into How PARPi Work

(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment…

Read on

FDA Approves Olaparib for Frontline Maintenance Treatment in Ovarian Cancer

(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage…

Read on

Neoadjuvant Chemotherapy Recommended for Stage IV Tubo-Ovarian Cancer

(December 7, 2018) A study published last month analyzed two clinical trials that sought to determine the best first step for advanced tubo-ovarian cancers, neoadjuvant chemotherapy or debulking surgery…

Read on

OCRA Holiday Card Raises Funds for a Cure

Holiday Greeting Cards that Give Back Send your friends and family customizable cards from Picaboo Cards for Causes and show your support for finding an ovarian cancer cure…

Read on

On #GivingTuesday, Join us in #GivingTeal to End Ovarian Cancer

#GivingTuesday is November 27th, and we need you to help us make a big impact! Please join us in #GivingTeal, for the 22,000 American women diagnosed with ovarian cancer every year, and the 200,000 living with this disease…

Read on

Simple Cysts Found by Ultrasound Don’t Require Action

(November 16, 2018) JAMA Internal Medicine recently published an eleven year study of over 72,000 women that found having a simple ovarian cyst does not increase one’s risk of ovarian cancer…

Read on